Background:
Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time. Half of all people with ALS live only 3 to 5 years after diagnosis. Current drug treatments can slow the progress of the disease, but they cannot stop or reverse it.
Objective:
To test a study drug (acamprosate) in people with ALS with a mutation in the C9orf72 gene.
Eligibility:
People aged 18 years and older with ALS. They must have a mutation in the C9orf72 gene.
Design:
Participants will have 13 visits over 32 weeks. Five visits will be at the clinic, and 8 visits will be by phone.
Participants will have a baseline visit of up to 3 days. They will have a physical exam with blood tests. They will have imaging scans and tests of their breathing ability. Their memory, thinking, and behavior will be assessed. They will have a neurologic exam to check their reflexes, strength, balance, eyes, and coordination. They will complete questionnaires about their daily life. They will have a lumbar puncture to collect fluid from the area around the spinal cord.
Acamprosate is a pill taken by mouth. Participants will take 2 pills by mouth 3 times a day with meals for 24 weeks. They will record their doses and any missed doses in a diary.
Baseline tests will be repeated during follow-up clinic visits. These tests may be spread out over 3 days.
During phone visits, participants will talk about how they are doing. They will review their diary with researchers.

Start Date02 Feb 2026

Sponsor / Collaborator

National Institute of Neurological Disorders & Stroke

NCT07060638

/ RecruitingPhase 2IIT

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).
The primary purpose of the study is to determine whether subjects receiving sAH therapy in addition to AUD treatments will have better alcohol and liver-related outcomes at 6 months compared to sAH therapy plus usual care for AUD. Patients assigned to the AUD treatment will receive Acamprosate and counseling whereas those assigned to AUD standard care will receive brief advice and referral to a 12-step program.
The secondary purpose of the study is to determine if F-652 is safe and effective in treating sAH when compared to prednisone. Subjects will receive F-652 on days 1 and 7 or prednisone for 28 days. Outcomes will be measured by overall survival at 90 days.

Start Date27 Jan 2026

Sponsor / Collaborator

Indiana University

[+1]

NCT06269627

/ RecruitingPhase 4IIT

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

Background:
Chronic heavy drinking can cause alcohol use disorder (AUD). AUD changes how the brain works. People with AUD may drink compulsively or feel like they cannot control their alcohol use. Acamprosate is an FDA-approved drug that reduces anxiety and craving in some, but not all, people with AUD.
Objective:
To learn more about how acamprosate affects brain function in people with AUD.
Eligibility:
People aged 21 to 65 years with moderate to severe AUD.
Design:
Participants will stay in the clinic for 21 days after a detoxification period of approximately 7 days.
Acamprosate is a capsule taken by mouth. Half of participants will take this drug 3 times a day with meals. The other half will take a placebo. The placebo looks like the study drug but does not contain any medicine. Participants will not know which capsules they are taking.
Participants will have a procedure called electroencephalography (EEG): A gel will be applied to certain locations on their scalp, and a snug cap will be placed on their head. The cap has sensors with wires. The sensors detect electrical activity in the brain. Participants will lie still and perform 2 tasks: they will look at different shapes and press a button when they see a specific one; and they will listen to tones and press dedicated buttons when they hear the corresponding tones.
Participants will have 2 EEGs: 1 on day 2 and 1 on day 23 of their study participation. They may opt to have up to 4 more EEG studies (one on day 13 and one on each of the three follow-up visits) and 2 sleep studies, in which they would have sensors attached to their scalp while they sleep.
Participants may have up to three follow-up visits for 6 months.

Start Date07 May 2025

Sponsor / Collaborator

National Institute on Alcohol Abuse & Alcoholism

100 Clinical Results associated with Acamprosate Calcium

100 Translational Medicine associated with Acamprosate Calcium

100 Patents (Medical) associated with Acamprosate Calcium

907

Literatures (Medical) associated with Acamprosate Calcium

01 Jul 2026·Journal of substance use and addiction treatment

Integrating addiction care in hepatology: Impact of liver consultation on post-discharge AUD treatment in alcohol-associated hepatitis

Article

Author: Cornet, Nicole ; Freedberg, Daniel ; Stoffel, Elina ; Lan, Nan ; Lin, Kevin

BACKGROUND:

Alcohol-associated hepatitis (AH) carries high short-term mortality and long-term morbidity. Current guidelines recommend that patients hospitalized with AH receive treatment for alcohol use disorder (AUD), including behavioral counseling and pharmacotherapy. However, integration of addiction treatment into routine inpatient care remains low. We evaluated whether inpatient hepatology consultation is associated with increased provision of AUD counseling and pharmacotherapy.

METHODS:

We conducted a retrospective cohort study of adults hospitalized with AH between January 2020 and July 2024 at a single academic center. AH was defined by ICD-10 code and NIAAA criteria. The primary exposure was liver service consultation. Primary outcomes were AUD counseling (dichotomized as referral provided vs. not) and pharmacotherapy (prescription vs. none). Multivariable logistic and mixed effects regression modeling was used to assess associations.

RESULTS:

There were 134 unique patients with 213 hospitalizations for AH. Median age was 47 years, 67% were male, and 73% were English-speaking. While nearly all patients (96%) received some form of counseling, only 17% were referred to structured rehabilitation programs and 30% received pharmacotherapy such as naltrexone, acamprosate, gabapentin and baclofen. In adjusted analyses, hepatology consultation (with or without GI involvement) was independently associated with higher odds of both referral to AUD treatment services (aOR 3.99, 95% CI 1.23-13.73 in a per-patient analysis and aOR 3.10, 95% CI 1.21-7.93 in a per-hospitalization analysis) and prescription of AUD pharmacotherapy (aOR 2.44, 95% CI 0.59-10.4 per-patient and aOR 3.74, 95% CI 1.16-12.06 per hospitalization).

CONCLUSIONS:

Despite hospitalization being a critical opportunity to initiate evidence-based AUD care, most patients with AH did not receive guideline-concordant treatment. Liver consultation services were associated with improved pharmacotherapy delivery and AUD referrals. Embedding addiction treatment protocols within hepatology pathways may improve delivery of AUD care and reduce disparities in this high-risk population.

03 Jun 2026·Expert Opinion On Drug Safety

Adverse drug event profile of pharmacotherapies for alcohol use disorder: a retrospective pharmacovigilance disproportionality analysis study

Article

Author: Sridharan, Kannan

BACKGROUND:

Alcohol Use Disorder (AUD) significantly affects global health, leading to physical deterioration and impacting personal and social relationships. This study aims to evaluate the adverse event profiles (AEP) of three USFDA-approved medications for AUD, acamprosate, disulfiram, and naltrexone, using data from the USFDA Adverse Event Reporting System (AERS).

RESEARCH DESIGNS AND METHODS:

Reports related to acamprosate, disulfiram, and naltrexone from March 2004 to March 2024 were extracted from the USFDA AERS database. Data were verified, and disproportionality analysis was conducted using frequentist and Bayesian methods. Adverse events were assessed based on reporting odds ratio, proportional reporting ratio, and Bayesian measures. Outcomes such as death, life-threatening events, and hospitalization were also analyzed.

RESULTS:

A total of 19,177 unique reports were analyzed (naltrexone: n = 18,544; acamprosate: n = 249; disulfiram: n = 384). Common adverse events included hepatobiliary, nervous system, and psychiatric disorders. Disulfiram was associated with coagulopathy and drug interactions, while naltrexone was linked to injection site reactions and hypersensitivity. Naltrexone had higher mortality reports, and disulfiram had more hospitalizations.

CONCLUSION:

The study underscores the diverse AEPs of these medications, highlighting the need for careful monitoring and individualized treatment to ensure safety and efficacy in managing AUD.

01 Jun 2026·ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Real‐World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP ‐1 Receptor Agonists Versus FDA ‐Approved AUD Medications

Article

Author: Gombar, Saurabh ; Pike, William ; Hui, Gavin ; Mirminachi, Babak ; Kwo, Paul ; Farokhnia, Mehdi ; Gougol, Amir

ABSTRACT:

Background:

Metabolic dysfunction (MetD) and alcohol use disorder (AUD) frequently coexist as synergistic risk factors for steatotic liver disease. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are established therapies for MetD, including type 2 diabetes mellitus (T2DM) and obesity. Recent studies suggested potential beneficial effects of GLP‐1RA to decrease addictive behaviours in AUD. We evaluated the outcomes of GLP‐1RA therapy compared with FDA‐approved pharmacotherapies for AUD, including naltrexone, acamprosate, and disulfiram, in patients with dual risk factors of MetD and AUD.

Methods:

We conducted a retrospective cohort study of patients at Stanford Health Care (2017–2025). Eligible patients had a concurrent diagnosis of alcohol‐related complications meeting criteria for AUD and MetD, including obesity (BMI > 25) and/or a history of T2DM with HbA1c > 5.7. Those with advanced liver disease within 1 year of diagnosis were excluded. Exposure groups included ≥ 6 months of GLP‐1RA therapy (semaglutide or tirzepatide) in comparison with FDA‐approved pharmacotherapies for AUD. Propensity score matching was employed to reduce the effects of confounding factors.

Results:

In total, 1946 patients were diagnosed concurrently with AUD and MetD. Of them, 274 patients were exposed to GLP‐1RA, 1272 to naltrexone, 232 to acamprosate, and 168 to disulfiram. Patients were followed for an average of 1341 days. Patients exposed to GLP‐1RA had higher BMI (35.5 vs. 30.1) and more T2DM (66% vs. 14%). GLP‐1RA therapy was associated with lower 1‐year AUD relapse [IRR 0.55, 95% CI 0.42–0.73; p < 0.01], greater BMI reduction (−1.3 vs. –0.3; p = 0.004), and HbA1c improvement (−1.0 vs. +0.1; p = 0.02). The incidence of decompensated cirrhosis trended lower but was not statistically significant [HR 0.52, p = 0.09]. Mortality was similar.

Conclusions:

GLP‐1RAs are a promising option for patients with concurrent MetD and AUD, improving relapse rates and metabolic outcomes compared with currently FDA‐approved pharmacotherapies for AUD. Trends toward better liver outcomes support further prospective evaluation.

News (Medical) associated with Acamprosate Calcium

27 May 2026

·www.einpresswire.com

Harmony Grove Connecting Clients With Medication-Assisted Treatment Providers in Houston, Texas

Harmony Grove blends evidence-based, and holistic outpatient treatment and community partnerships for MAT to create an environment focused on lasting recovery. HOUSTON, TX, UNITED STATES, May 27, 2026 / EINPresswire.com / -- Harmony Grove Behavioral Health in Houston emphasizes its partnership-based approach to medication-assisted treatment (MAT) , connecting clients with local MAT providers and medication management while delivering comprehensive outpatient services that integrate clinical care with a broader healing community. This coordinated model personalizes treatment plans and combines evidence-based therapies, holistic support, and family involvement to strengthen long-term recovery from opioid and alcohol use disorders. Harmony Grove does not operate MAT programs directly but partners with local Houston facilities to ensure clients have access to FDA-approved medications and professional medication management alongside outpatient services. This collaborative approach allows Harmony Grove to tailor each client’s program while integrating resources across the city, creating a culture of support that helps individuals fully engage in therapy and recovery. Medication-assisted treatment uses prescribed medications to target symptoms of addiction, support withdrawal management, reduce cravings, and create stability that enables meaningful participation in counseling and peer-based therapies. MAT is not a stand-alone solution; it functions as a complementary component of a holistic treatment plan that includes individual and group therapy, evidence-based modalities, and ongoing follow-up care. Managing withdrawal and cravings with medication can empower clients to better engage with CBT, DBT, motivational interviewing, EMDR, and relapse prevention work, improving retention in treatment and reducing the risk of overdose. Harmony Grove’s partnerships make a range of FDA-approved medications available, as appropriate for the individual client. Options include buprenorphine and Suboxone for outpatient opioid treatment, methadone for severe cases managed through specialized clinics, naltrexone for relapse prevention following detox, naloxone for overdose, and medications such as acamprosate and disulfiram for alcohol dependence. Clinicians work with clients to determine the most suitable medication strategy, recognizing that medication selection depends on clinical history, treatment goals, and the stage of recovery. Harmony Grove serves adults in Houston who struggle with opioid addiction, alcohol dependence, and co-occurring mental health disorders. The outpatient program emphasizes individualized treatment planning that accounts for trauma history, mental health conditions, and psychosocial needs. Medication-assisted treatment is integrated with individual counseling, group therapy, experiential interventions, and holistic support, including nutrition, movement, and mind-body practices. This whole-person approach helps clients address underlying drivers of substance use and develop life skills necessary for sustainable sobriety. As a dedicated outpatient facility, Harmony Grove offers in-person and flexible scheduling options for individuals balancing recovery with work, school, or family responsibilities. Outpatient care is designed to make treatment accessible without sacrificing intensive therapeutic support. MAT services provided through local partners are coordinated with Harmony Grove’s clinicians to ensure continuity of care and timely adjustments to medication management as recovery needs evolve. Family involvement and community are key elements to their program, as connection is essential to recovery. Family integration into intensive outpatient and aftercare programs provides education, communication strategies, and follow-up counseling that support both clients and loved ones. Peer and alumni support add community-based encouragement that reduces isolation and reinforces positive change. Harmony Grove combines MAT with evidence-based therapies, including cognitive-behavioral therapy, dialectical behavior therapy, motivational interviewing, and EMDR. The program seeks to improve treatment retention, reduce overdose risk, and support better behavioral health outcomes through a balanced mix of clinical rigor and compassionate community. For more information about how MAT may fit into your recovery plan or to discuss outpatient options, contact the admissions team at Harmony Grove today. Matt Handy Harmony Grove Behavioral Health +1 713-564-6468 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

18 Oct 2025

·www.sciencedaily.com

Can Ozempic help you cut back on alcohol? Researchers think so

Semaglutide, tirzepatide, and other GLP-1 drugs appear to slow alcohol absorption and blunt its intoxicating effects, according to new research. The study found participants on these medications felt less drunk despite consuming the same amount of alcohol. This could point to a safer, faster-acting way to help people reduce drinking—distinct from traditional treatments that target the brain directly. Growing research suggests that medications commonly prescribed for diabetes and weight loss (including the well-known Ozempic and Wegovy) might also help people drink less alcohol. A new study from the Fralin Biomedical Research Institute at VTC, published this month in Scientific Reports, found that GLP-1 agonists appear to slow how quickly alcohol moves into the bloodstream, which in turn delays its effects on the brain. "People who drink know there's a difference between nursing a glass of wine and downing a shot of whiskey," said Alex DiFeliceantonio, assistant professor and interim co-director of the FBRI's Center for Health Behaviors Research. Although a standard serving of each contains the same amount of alcohol (0.6 ounces), a shot causes blood-alcohol levels to rise much faster. That quick spike feels stronger because of how the body absorbs and processes alcohol. "Why would this matter? Faster-acting drugs have a higher abuse potential," DiFeliceantonio said. "They have a different impact on the brain. So if GLP-1s slow alcohol entering the bloodstream, they could reduce the effects of alcohol and help people drink less." More than half of U.S. adults consume alcohol, and about one in ten has an alcohol use disorder. Chronic, heavy drinking is linked to conditions such as high blood pressure, heart and liver disease, and several cancers. Earlier this year, U.S. Surgeon General Vivek Murthy identified alcohol use as the nation's third leading preventable cause of cancer, following tobacco use and obesity. In the study, participants who were taking GLP-1 medications such as semaglutide, tirzepatide, or liraglutide experienced a slower rise in blood-alcohol concentration even though they consumed the same amount of alcohol as those not on the drugs. They also reported feeling less intoxicated based on their own assessments. Supported by funding from Virginia Tech's Fralin Biomedical Research Institute, the study aimed to explore both the physical and perceived effects of alcohol in people taking a GLP-1 drug. The researchers say these early findings could help shape larger, long-term studies on whether such medications might be used to reduce alcohol consumption. The study included twenty adults with a body mass index (BMI) of 30 or higher, half of whom were taking GLP-1 medication and half who were not. Participants were asked to fast before the session, then were given a snack bar to keep stomach contents consistent. Researchers measured each participant's blood pressure, pulse, breath alcohol concentration, and blood glucose levels. Ninety minutes later, they were served an alcoholic drink to finish within 10 minutes. Afterward, participants were asked several times over an hour to describe their level of intoxication, cravings, appetite, and the drink's taste, including the question, "How drunk do you feel right now?" rated from zero to ten. Those on GLP-1 medication consistently reported feeling less drunk. After the drinking portion ended, participants stayed in a recovery area while their alcohol levels dropped. Breath alcohol was measured every 30 minutes, blood glucose twice, and after three hours participants again answered follow-up questions. Four hours later, once their breath alcohol measured below 0.02 percent and they were cleared by a study physician, they were allowed to leave. "Other medications designed to help reduce alcohol intake" -- naltrexone and acamprosate -- "act on the central nervous system," said DiFeliceantonio, the study's corresponding author. "Our preliminary data suggest that GLP-1s suppress intake through a different mechanism." The drugs slow gastric emptying, which can lead to a slower rise in blood alcohol. The idea for the study initially bubbled up during a Fralin Biomedical Research Institute faculty retreat and was led by Warren Bickel, professor and director of the Addiction Recovery Research Center, who died in 2024. It built on an analysis of social media posts on the community network Reddit, in which users reported reduced cravings for alcohol when taking drugs intended to treat type 2 diabetes and obesity. "His guidance shaped every stage of this research -- from the initial idea to its final form -- and his passion for scientific discovery continues to inspire me every day," said Fatima Quddos, a graduate researcher in Bickel's lab and the first author on both studies. "Bickel's work had long focused on what happens when you delay rewards, so we asked, 'What if GLP-1s affect how the body handles alcohol?'" DiFeliceantonio said. "Ending this project was bittersweet, because it was my last collaboration with him." "He was always asking, 'How do we help people the fastest?' Using a drug that's already shown to be safe to help people reduce drinking could be a way to get people help fast," DiFeliceantonio said. While this was a pilot study, researchers said the findings showed clear differences between groups and provide early data that support larger trials testing the drugs as a therapy for people who want to reduce their alcohol use. "As a recent graduate, I'm deeply inspired by the potential this research holds -- not only for advancing our scientific understanding, but also for paving the way toward future therapies," said Quddos, who earned her doctorate from Virginia Tech's Translational Biology, Medicine, and Health Graduate Program in May. "The possibility of offering new hope to individuals struggling with addiction is what makes this work so meaningful."

Clinical Result

16 Oct 2025

·www.drugs.com

Why Might GLP-1 Drugs Reduce Alcohol Cravings? New Experiment Suggests An Answer

THURSDAY, Oct. 16, 2025 — Weight-loss drugs like Ozempic and Zepbound appear to reduce alcohol cravings, but doctors have been at a loss to explain why – until now. Glucagon-like peptide-1 (GLP-1) drugs appear to slow the speed at which alcohol enters the bloodstream, which also diminishes its effects on a person’s brain, according to pilot study results published Oct. 15 in the journal Scientific Reports . Essentially, people don’t feel the effects of alcohol as intensely if they’re taking a GLP-1 med, researchers said. “People who drink know there’s a difference between nursing a glass of wine and downing a shot of whiskey,” researcher Alex DiFeliceantonio said in a news release. She’s interim co-director of the Roanoke, Virginia-based Fralin Biomedical Research Institute at VTC’s Center for Health Behaviors Research. Both drinks contain the same amount of alcohol, but the shot brings a rapid increase in blood-alcohol content and, subsequently, intoxication, DiFeliceantonio said. “Why would this matter? Faster-acting drugs have a higher abuse potential,” she said. “They have a different impact on the brain. So if GLP-1s slow alcohol entering the bloodstream, they could reduce the effects of alcohol and help people drink less.” GLP-1 drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. For the new study, researchers recruited 20 people with obesity, half of whom were taking a GLP-1 drug. All had a body mass index (BMI) of 30 or more. BMI is an estimate of body fat based on height and weight. The participants were served an alcoholic beverage that had to be consumed within 10 minutes. Researchers measured their breath alcohol and asked them questions about how they felt, such as “How drunk do you feel right now?” on a scale from 1 to 10. This process was repeated three times over an hour, researchers said. In the end, people taking GLP-1 drugs consistently reported feeling less intoxicated, the study found. Data taken during the experiment indicated that GLP-1 drugs’ ability to slow stomach emptying likely reduces the effect of alcohol, researchers said. Other drugs designed to help reduce alcohol intake act upon the nervous system, researchers noted. For example, acamprosate stabilizes neurotransmitter activity in the brain, offsetting the effects of alcohol. “Our preliminary data suggest that GLP-1s suppress intake through a different mechanism,” DiFeliceantonio said. Researchers said this could open up another means of helping people battle alcoholism , but larger clinical trials are needed to confirm this. Sources Fralin Biomedical Research Institute at VTC, news release, Oct. 15, 2025

100 Deals associated with Acamprosate Calcium

External Link

KEGG	Wiki	ATC	Drug Bank
D02780	Acamprosate Calcium	N07BB03	DB00659

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alcoholism	United States	Forest Laboratories, Inc.	29 Jul 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Binge-Eating Disorder	Phase 3	United States	Forest Laboratories LLC	01 Apr 2007
Schizophrenia	Phase 3	United States	Forest Laboratories LLC	01 Sep 2006
Stress Disorders, Post-Traumatic	Phase 2	-	Synchroneuron, Inc.	01 Jun 2016
Tourette Syndrome	Phase 2	United States	Synchroneuron, Inc.	01 Apr 2015
Tardive Dyskinesia	Phase 2	United States	Synchroneuron, Inc.	01 Feb 2014
Methamphetamine dependence	Phase 2	United States	Forest Laboratories LLC	01 Jul 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03818191 (CTgov)	Phase 4	Alcohol Use Disorder	288	Acamprosate (Acamprosate)	memqlkkzbo = pkfxblltfn wqvuwcoral (nvxticwkcq, rrzpzqlvyi - pwksrajanu) View more	-	17 Dec 2024
				Placebo (Placebo)	memqlkkzbo = gaazdzpozz wqvuwcoral (nvxticwkcq, mouabdxqsy - ukvygjyxia) View more
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	Not Applicable	Liver Diseases, Alcoholic	-	Naltrexone	nltbujmzif(zfabhaiazw) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI radguwusue (mdinlcmlno ) View more	-	20 May 2024
				Acamprosate
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	Not Applicable	Liver Diseases, Alcoholic	-	Naltrexone	huncxuiosf(ldnyiaczhk) = hijwvuzcfi agrsyepyoh (nxwgcsdvor )	-	20 May 2024
				Acamprosate	huncxuiosf(ldnyiaczhk) = orckozxxnx agrsyepyoh (nxwgcsdvor )
NCT04287920 (CTgov)	Phase 2	Alcohol Use Disorder \| Hepatitis, Alcoholic \| Liver Diseases, Alcoholic	12	Acomprosate (Alcohol-related Liver Disease and AUD, MELD-NA Less Than 20)	zukcvnsuev = ypbqjvjwjq rmqpyaeqqx (gwdxpeqkre, bgdskunxfm - bldbpqcvpn) View more	-	20 Dec 2022
				Acomprosate (Alcohol-related Liver Disease and AUD, MELD-NA More Than 20)	zukcvnsuev = ibnzxdvwar rmqpyaeqqx (gwdxpeqkre, ygykpimjdc - lmpbfdomgf) View more
NCT02998151 (CTgov)	Early Phase 1	Fragile X Syndrome	29	placebo (Placebo)	yxndxyotuj(doqrcjoals) = jmzjbbxexs rwkayiaovn (tovfiqnbrh, .0265) View more	-	24 Nov 2021
				Acamprosate (Acamprosate)	yxndxyotuj(doqrcjoals) = jbdykfhhbs rwkayiaovn (tovfiqnbrh, 0.0252) View more
NCT00466661 (CTgov)	Phase 4	Alcoholism \| Bipolar Disorder \| Bipolar II disorder	33	Acamprosate (Acamprosate)	jvoqjlztkr(eylpdiujlp) = uwradooacw rsigoevbso (nyskvnckci, ziupnftaxp - oalfzpinry) View more	-	14 Dec 2018
				Placebo (Placebo)	jvoqjlztkr(eylpdiujlp) = sxtelkxxqp rsigoevbso (nyskvnckci, pwtusbbykb - urwleutvjx) View more
NCT01300923 (CTgov)	Phase 2	Autism Spectrum Disorder \| Fragile X Syndrome	14	Acamprosate	zmruwaxdso(sblgyzvdsg) = ichdjwmpcc dramzckujr (lzocrcqckm, xwywdpmhzq - kjfntjgdqr) View more	-	28 Apr 2017
NCT00571922 (AcampMet, CTgov)	Phase 1/2	Methamphetamine dependence	72	Acamprosate (Acamprosate)	unrzylfvna(tfobfvfgdb) = axxeryuiwj mdnsbvweoj (zmhyrzvypx, qhobbvgpnw - pfmlnmupyf) View more	-	06 Apr 2016
				placebo (Placebo)	unrzylfvna(tfobfvfgdb) = jjpqwynsjc mdnsbvweoj (zmhyrzvypx, anthwpmoqp - uxffmuvmei) View more
NCT00463346 (CTgov)	Phase 3	Alcoholism \| Schizophrenia	23	Acamprosate (Acamprosate)	vjlrqekphs(oocpeomvjt) = rhlhokjhtq viuuxejfqj (tbvbxbnczn, 17.11) View more	-	15 Jan 2016
				Placebo (Placebo)	vjlrqekphs(oocpeomvjt) = rqgahhjlig viuuxejfqj (tbvbxbnczn, 11.5) View more
NCT00330174 (CTgov)	Phase 4	Alcoholism \| Phobia, Social \| Depressive Disorder, Major ... View more	90	Acamprosate (Acamprosate)	robglgdude(olbhambekt) = qghwtxlghp hrxqzwtcnw (auzpoelcci, 0.04) View more	-	13 Apr 2015
				placebo (Placebo)	robglgdude(olbhambekt) = wfuirefeuo hrxqzwtcnw (auzpoelcci, 0.04) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis